Cargando…

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation

Limited clinical application of antibody-drug conjugates (ADCs) targeting tumor associated antigens (TAAs) is usually caused by on-target off-tumor side effect. Tumor-specific mutant antigens (TSMAs) only expressed in tumor cells which are ideal targets for ADCs. In addition, intracellular somatic m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Ying, Wei, Xiaoyue, Jin, Shijie, Wu, Yue, Zhao, Wenbin, Xu, Yingchun, Pan, Liqiang, Zhou, Zhan, Chen, Shuqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shenyang Pharmaceutical University 2020
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750800/ https://www.ncbi.nlm.nih.gov/pubmed/33363632 http://dx.doi.org/10.1016/j.ajps.2020.01.002

Ejemplares similares

The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein
por: Shen, Ying, et al.
Publicado: (2019)

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models
por: Fan, Jiansheng, et al.
Publicado: (2021)

Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
por: Ai, Qi, et al.
Publicado: (2023)

Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody
por: Dao, Tao, et al.
Publicado: (2019)

Searching for treatments for non-G12C-KRAS mutant cancers
por: Guo, Christina, et al.
Publicado: (2021)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy
por: Bai, Xuefei, et al.
Publicado: (2021)

De Novo KRAS G12C–Mutant SCLC: A Case Report
por: Balbach, Meridith L., et al.
Publicado: (2022)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant KRAS antigens
por: Ng, Allan Wee Ren, et al.
Publicado: (2018)

In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”
por: Moore, Margaret, et al.
Publicado: (2022)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
por: Kalim, Muhammad, et al.
Publicado: (2017)

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
por: Caiola, Elisa, et al.
Publicado: (2015)

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
por: Araujo, Luiz Henrique, et al.
Publicado: (2021)

Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors
por: Akkapeddi, Padma, et al.
Publicado: (2023)

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates
por: Xu, Ying, et al.
Publicado: (2017)

TCR-mimic bispecific antibodies to target the HIV-1 reservoir
por: Sengupta, Srona, et al.
Publicado: (2022)

The measurement of KRAS G12 mutants using multiplexed selected reaction monitoring and ion mobility mass spectrometry
por: Norman, Rachel L, et al.
Publicado: (2020)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Transposable element RNA dysregulation in mutant KRAS(G12C) 3D lung cancer spheroids
por: Carrillo, David, et al.
Publicado: (2023)

Author Reply: In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”
por: Balbach, Meridith L., et al.
Publicado: (2022)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer
por: Chiou, Li-Wen, et al.
Publicado: (2023)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

KRAS(G12) mutant induces the release of the WSTF/NRG3 complex, and contributes to an oncogenic paracrine signaling pathway
por: Liu, Yan, et al.
Publicado: (2016)

Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression
por: Jiang, Wang, et al.
Publicado: (2020)

Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression
por: Gao, Qianqian, et al.
Publicado: (2020)

KRAS G12C-Mutant Non-Small-Cell Lung Adenocarcinoma: First Documented Report in the Arabian Gulf
por: Alsulaiman, Abdullah S, et al.
Publicado: (2022)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma
por: Liu, Chang, et al.
Publicado: (2022)

TCR mimic compounds for pHLA targeting with high potency modalities in oncology
por: Gerber, Hans-Peter, et al.
Publicado: (2022)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy
por: Zhao, Qingci, et al.
Publicado: (2023)

Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study
por: Srisongkram, Tarapong, et al.
Publicado: (2022)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6igebaoeof6soind78gtlbq3f0